Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase 1/2 study of ponatinib in recurrent or refractory leukemias and solid tumors
2023-509699-41-00Phase 2Authorised
- Sponsor
- Incyte
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of ponatinib in leukemia, lymphoma, Nonhematologic neoplasms and 4 more (3 arms), sponsored by Incyte. Primary endpoints: Dose-limiting toxicities, Major cytogenetic response and 4 more. Planned start Jan 2024; status: authorised.
02
Drugs
ponatinib
03
Conditions
leukemialymphomaNonhematologic neoplasmschronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2023-509699-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509699-41-00.